Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.65 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585124 | 1.00 | USP2 (0.65) | USP2SLCO1B1SLC7A5PDE4AOR51E2 | |
| SCHEMBL15423731 | 1.00 | USP2 (0.65) | USP2SLCO1B1SLC7A5PDE4AOR51E2 | |
| SCHEMBL23097183 | 1.00 | USP2 (0.65) | USP2SLCO1B1SLC7A5PDE4AOR51E2 | |
| SCHEMBL28890361 | 0.92 | USP2 (0.57) | USP2SLCO1B1SLC7A5PDE4AOR51E2 | |
| SCHEMBL28890360 | 0.86 | USP2 (0.50) | USP2SLCO1B1SLC7A5PDE4A | |
| SCHEMBL13502514 | 0.82 | USP2 (0.48) | USP2SLCO1B1SLC7A5TP53SLC1A1 | |
| SCHEMBL4962916 | 0.82 | USP2 (0.48) | USP2SLCO1B1SLC7A5TP53SLC1A1 | |
| SCHEMBL13502486 | 0.82 | USP2 (0.48) | USP2SLCO1B1SLC7A5TP53SLC1A1 | |
| SCHEMBL3574674 | 0.82 | USP2 (0.48) | USP2SLCO1B1SLC7A5TP53SLC1A1 | |
| SCHEMBL13502425 | 0.82 | USP2 (0.48) | USP2SLCO1B1SLC7A5TP53SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001836-A1 | METHODS FOR PREPARING (2S,3R,4R)-4,5-DIHYDROXYISOLEUCINE DERIVATIVE AND INTERMEDIATES THEREOF | UNIV INNER MONGOLIA (CN) | 2026-01-01 | — | — | US | claimed |
| US-20250282826-A1 | PREPARATION METHOD, INTERMEDIATES, AND USE OF CYCLIC PEPTIDE TOXIN ALPHA-AMANITIN AND/OR AMANINAMIDE | INNER MONGOLIA UNIVERSITY (CN) | 2025-09-11 | — | — | US | claimed |
| EP-3661938-B1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA RES GMBH (DE) | 2025-01-15 | — | — | EP | claimed |
| WO-2024243706-A1 | AMATOXIN ANALOGS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-12-05 | — | — | WO | claimed |
| WO-2024188374-A2 | PREPARATION METHOD FOR (2S,3R,4R)-4,5-DIHYDROXY ISOLEUCINE DERIVATIVE AND INTERMEDIATE | 内蒙古大学 | 2024-09-19 | — | — | WO | claimed |
| CN-117843525-B | Preparation method of (2S, 3R, 4R) -4, 5-dihydroxyisoleucine derivative and intermediate | 内蒙古大学 | 2024-06-04 | — | — | CN | claimed |
| CN-112585116-B | Synthesis of (2S, 3R, 4R) -4, 5-dihydroxyisoleucine and derivatives thereof | 海德堡医药研究有限责任公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117843525-A | Preparation method of (2S, 3R, 4R) -4, 5-dihydroxyisoleucine derivative and intermediate | 内蒙古大学 | 2024-04-09 | — | — | CN | claimed |
| US-20240082416-A1 | AMATOXIN ANALOGS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-14 | — | — | US | claimed |
| CN-111432844-B | PSMA-targeting amanitine conjugates | 海德堡医药研究有限责任公司 | 2023-10-27 | — | — | CN | claimed |
| US-9676702-B2 | Methods for synthesizing amatoxin building block and amatoxins | HEIDELBERG PHARMA GMBH (DE) | 2017-06-13 | — | — | US | claimed |
| US-9630907-B2 | — | — | 2017-04-25 | — | — | US | claimed |
| CN-104470891-B | Method for synthesizing amatoxin building block and amatoxin | 海德堡医药有限责任公司 | 2016-10-12 | — | — | CN | claimed |
| EP-2872479-B1 | METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS | HEIDELBERG PHARMA GMBH (DE) | 2016-06-08 | — | — | EP | claimed |
| US-20150210628-A1 | METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS | HEIDELBERG PHARMA GMBH (DE) | 2015-07-30 | — | — | US | claimed |
| EP-2872479-A1 | METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS | Heidelberg Pharma GmbH (DE) | 2015-05-20 | — | — | EP | claimed |
| CN-104470891-A | Method for synthesizing amatoxin building block and amatoxin | HEIDELBERG PHARMA GMBH | 2015-03-25 | — | — | CN | claimed |
| WO-2014009025-A1 | METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS | HEIDELBERG PHARMA GMBH (DE) | 2014-01-16 | — | — | WO | claimed |
| EP-2684865-A1 | Methods for synthesizing amatoxin building block and amatoxins | Heidelberg Pharma GmbH (DE) | 2014-01-15 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282826-A1 | PREPARATION METHOD, INTERMEDIATES, AND USE OF CYCLIC PEPTIDE TOXIN ALPHA-AMANITIN AND/OR AMANINAMIDE | VIP, PTMA, MLEC | USP2 4115/4885SLCO1B1 4098/4885SLC7A5 865/4885 |
| US-20150210628-A1 | METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS | MEP1B, VIP, NMBR | USP2 4144/4885SLCO1B1 4746/4885SLC7A5 290/4885 |
| US-20240082416-A1 | AMATOXIN ANALOGS AND USES THEREOF | VIP, MTX1, APLNR | USP2 4773/4885SLCO1B1 4211/4885SLC7A5 184/4885 |
| US-20260001836-A1 | METHODS FOR PREPARING (2S,3R,4R)-4,5-DIHYDROXYISOLEUCINE DERIVATIVE AND INTERMEDIATES THEREOF | GRIA4, GRIK4, DHPS | USP2 4322/4885SLCO1B1 3783/4885SLC7A5 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.